Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

    Circulation Date published:

  • Risk factors for incident kidney disease in older adults: an Australian prospective population-based study

    Internal Medicine Journal Date published:

  • Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • SGLT2 inhibitors and finerenone: one or the other or both?

    Nephrology Dialysis Transplantation Date published:

  • Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

    Clinical Journal of the American Society of Nephrology Date published:

  • Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression

    Journal of the American Society of Nephrology Date published:

  • Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure

    Date published:

  • Interleukin-6 and cardiovascular outcome in patients with type 2 diabetes: new insights from CANVAS

    Diabetologia Date published:

  • Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial

    Journal of the American Heart Association Date published:

  • Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities

    Cardiorenal Medicine Date published:

  • Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

    European Heart Journal Date published:

  • Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression

    American Journal of Kidney Diseases Date published:

  • Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

    Diabetologia Date published:

  • Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

    European Heart Journal Date published:

  • Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

    Diabetologia Date published:

  • Chronic kidney disease

    The Lancet Date published: